Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Axsome Therapeutics, Inc.
AXSM
NASDAQ·Healthcare·Biotechnology·Mkt cap $12.4B
$244.31
▲ +1.52%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$96.09 - $260.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 131.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced multi-mechanistic drug development
- Diverse clinical-stage pharmaceutical pipeline
- Strategic research collaborations
- Focused neurological treatment expertise
Bear Case
2 risks
- Low volatility (beta 0.6).
- Growth premium of 17.6x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Growth
Turning profitable
Expanding CNS treatment market
Value
Growth premium of 17.6x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+42.8% over 3m
Quality
Excellent
High-growth business (64% revenue growth, 93% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying AXSM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 3, 2026
MAY 4, 2026
Reported EPS of -$1.26 vs -$0.85 consensus (-48.2% surprise). Revenue of $189.4M vs $191.1M expected (-0.9%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-48.2%
Next: Aug 3, 2026
Revenue trend · last 8Q
—
—
+66%
+62%
+72%
+63%
+65%
+57%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$87.2M
$104.8M
$118.8M
$121.5M
$150.0M
$171.0M
$196.0M
$191.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-33.8%
Wall Street consensus
13 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$267.00
▲ +9.3% vs $244.31
Latest: TD Cowen · Jun 17, 2026
12 analysts covering